loader image

Unlocking the potential of epigenetic therapeutics to revolutionize medicine

DURECT harnesses epigenetic regulation to treat acute and chronic organ injury. Our unique approach has the potential to change the course of disease and improve patients’ lives.

Epigenetic Regulation

Many types of organ injuries and chronic diseases are associated with dysregulation of the epigenome. There is vast potential for epigenetic therapies to address the underlying pathology of disease by mitigating epigenomic dysregulation and helping to improve cellular function.1-3

Alcohol-Associated Hepatitis (AH)

Our first epigenetic therapy, larsucosterol (DUR-928), may have the potential to become a new standard of care for patients with AH based on outcomes from clinical trials to date.4

Clinical Trials

We are currently conducting a Phase 2b study (AHFIRM) in subjects with Alcohol-Associated Hepatitis (AH) in more than 60 clinical trial sites across the US, EU, UK, and Australia.

Scientists working in a lab

Partner with us

We welcome strategic partnerships to advance our collective goal to meaningfully impact patients’ lives and offer better therapeutic options.

Careers

Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies.

While there are no current openings, be sure to check back often to see what new jobs are posted.

Press Releases

DURECT Announces 1-for-10 Reverse Stock Split

 Nov 28, 2022, 18:46 ET  CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs

References

  1. Argemi J, Latasa MU, Atkinson SR, et al. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nat Commun. 2019;10(1):3126. doi:10.1038/s41467-019-11004-3
  2. Mazzone R, Zwergel C, Artico M, et al. The emerging role of epigenetics in human autoimmune disorders. Clin Epigenetics. 2019;11(1):34. doi:10.1186/s13148-019-0632-2
  3. Herman A, Occean JR, Sen P. Epigenetic dysregulation in cardiovascular aging and disease. J Cardiovasc Aging. 2021;1:10. doi:10.20517/jca.2021.16
  4. Hassanein T, Stein L, Flamm S, et al. Safety and efficacy of DUR-928: A potential new therapy for acute alcoholic hepatitis. Late-breaking oral presentation at AASLD The Liver Meeting®; 2019 November 12.
Scroll to Top